DOCSLIB.ORG

Are We Aware of the Risk of Eye Irritation Caused by Some Eyedrops, Paradoxically, in the Treatment of Allergic Conjunctivitis ?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Are We Aware of the Risk of Eye Irritation Caused by Some Eyedrops, Paradoxically, in the Treatment of Allergic Conjunctivitis ? Patient Patient PS-035 ARE WE AWARE OF THE RISK OF EYE IRRITATION CAUSED safety and BY SOME EYEDROPS, PARADOXICALLY, risk management Morocco IN THE TREATMENT OF ALLERGIC CONJUNCTIVITIS ? Younes Rahali* *Hospital Pharmacy, Specialties Hospital of Rabat, University Mohammed V, Rabat, Morocco / [email protected] OBJECTIVES The formulation of eye drops needs to prevent any microbial contamination of the eye. For this purpose, pharmaceutical manufacturer can use: the addition of a preservative, the use of a specific packaging including a sterilising filter or a single dose packaging. The purpose of the study is to check if the contents of eye drops indicated for the treatment of allergic conjunctivitis can be irritating for the eye. METHODS For this purpose, based on Vidal® 2013, we searched for eye drops used in allergic conjunctivitis and we analysed their excipient formulas searching for those known irritating to the eye. RESULTS The 21 analysed formulas revealed that the benzalkonium chloride is the only preservative used in this context. Although it is classified as an excipient known to be irritating to the eye, it is still used in 11 cases and cited as an excipient with known effect in only 1 case, while for the rest it is cited as an antimicrobial preservative. The single-dose packaging is used in 7 cases while the packaging including a sterilising filter is used in only 3 cases. INN (INTERNATIONAL PRESERVATIVE BRAND NAME EXCIPIENTS PACKAGING NON-PROPRIETARY NAME) (NF = NOT FOUND) SODIUM CHLORIDE, DODECAHYDRATE DISODIUM PHOSPHATE, MULTIDOSE INCLUDING CROMABAK® EYEDROPS NF DISODIUM PHOSPHATE DIHYDRATE, WATER WFI (WATER FOR INJECTION) A STERILISING FILTER EDETATE SODIUM, POLYSORBATE 80, SORBITOL, SODIUM HYDROXIDE, CROMEDIL® EYEDROPS BENZALKONIUM CHLORIDE MULTIDOSE WATER WFI. PRESERVATIVE: BENZALKONIUM CHLORIDE CROMEDIL® EYEDROPS SODIUM CHLORIDE, WATER WFI NF SINGLE-DOSE CROMOGLICIC ACID HUMEX® EYEDROPS SODIUM CHLORIDE, WATER WFI NF SINGLE-DOSE SODIUM CHLORIDE, DODECAHYDRATE DISODIUM PHOSPHATE, MULTIDOSE INCLUDING MULTICROM® EYEDROPS NF DISODIUM PHOSPHATE DIHYDRATE, WATER WFI A STERILISING FILTER MULTICROM® EYEDROPS SODIUM CHLORIDE, WATER WFI NF SINGLE-DOSE OPTICRON® EYEDROPS EDETATE SODIUM, BENZALKONIUM CHLORIDE, WATER WFI BENZALKONIUM CHLORIDE MULTIDOSE OPTICRON® EYEDROPS SODIUM CHLORIDE, WATER WFI NF SINGLE-DOSE MULTIDOSE INCLUDING NAABAK® EYEDROPS SODIUM HYDROXIDE OR HYDROCHLORIC ACID FOR PH 7.2, WATER WFI NF A STERILISING FILTER NAAXIA® 19,6 MG/0,4 ML SODIUM HYDROXIDE OR HYDROCHLORIC ACID FOR PH 7.2, WATER WFI. SPAGLUMIC ACID BENZALKONIUM CHLORIDE MULTIDOSE EYEDROPS PRESERVATIVE: BENZALKONIUM CHLORIDE SODIUM HYDROXIDE OR HYDROCHLORIC ACID FOR PH 7.2, WATER WFI. NAAXIA® EYEDROPS BENZALKONIUM CHLORIDE MULTIDOSE PRESERVATIVE: BENZALKONIUM CHLORIDE AZELASTINE BENZALKONIUM CHLORIDE, HYPROMELLOSE, EDETATE SODIUM, ALLERGODIL® EYEDROPS BENZALKONIUM CHLORIDE MULTIDOSE HYDROCHLORIDE SORBITOL, SODIUM HYDROXIDE, WATER WFI ISODRIL PHENYLEPHRINE® MANNITOL, SODIUM GLUCONATE, EDETATE SODIUM, WATER WFI NF SINGLE-DOSE CHLORHEXIDINE EYEDROPS DIGLUCONATE VISIODOSE® EYEDROPS MANNITOL, POTASSIUM GLUCONATE, EDETATE SODIUM, WATER WFI NF SINGLE-DOSE SODIUM HYDROGEN PHOSPHATE, POLYSORBATE 80, SODIUM CHLORIDE, DEXAMETHASONE MAXIDEX® EYEDROPS BENZALKONIUM CHLORIDE MULTIDOSE METHYLHYDROXYPROPYLCELLULOSE, CITRIC ACID, WATER WFI BENZALKONIUM CHLORIDE, METHYLHYDROXYPROPYLCELLULOSE, FLUOROMETHOLONE FLUCON® EYEDROPS SODIUM HYDROGEN PHOSPHATE, POLYSORBATE 80, SODIUM CHLORIDE, BENZALKONIUM CHLORIDE MULTIDOSE EDETATE SODIUM, POLYVINYL ALCOHOL, WATER WFI LEVOCABASTINE PROPYLENE GLYCOL, SODIUM HYDROGEN PHOSPHATE, HYPROMELLOSE, LEVOPHTA® EYEDROPS BENZALKONIUM CHLORIDE MULTIDOSE HYDROCHLORIDE POLYSORBATE 80, WATER WFI BENZALKONIUM CHLORIDE, MANNITOL, EDETATE SODIUM, METHYLHYDROXYPROPYLCELLULOSE, SODIUM CITRATE, CITRIC ACID, ALMIDE® EYEDROPS BENZALKONIUM CHLORIDE MULTIDOSE TYLOXAPOL, SODIUM HYDROXIDE OR HYDROCHLORIC ACID FOR PH 7.2, LODOXAMIDE WATER WFI TROMETHAMINE MANNITOL, HYPROMELLOSE 2910, SODIUM CITRATE, CITRIC ACID, ALMIDE® EYEDROPS TYLOXAPOL, SODIUM HYDROXIDE OR HYDROCHLORIC ACID FOR PH 7.2, NF SINGLE-DOSE WATER WFI BENZALKONIUM CHLORIDE, EDETATE SODIUM, SODIUM CHLORIDE, NEDOCROMIL SODIUM TILAVIST® EYEDROPS BENZALKONIUM CHLORIDE MULTIDOSE WATER WFI MANNITOL, CARBOMERE (CARBOPOL 974 P), POLYSORBATE 80, SODIUM RIMEXOLONE VEXOL® EYEDROPS CHLORIDE, EDETATE SODIUM, SODIUM HYDROXIDE OR HYDROCHLORIC BENZALKONIUM CHLORIDE MULTIDOSE ACID FOR PH 7.2, WATER WFI. PRESERVATIVE: BENZALKONIUM CHLORIDE DISCUSSION From these results we see that benzalkonium chloride is widely used. On the other hand, treating allergic conjunctivitis by a potentially irritating drug can be problematic when induced irritation takes over the symptoms of the allergy. This can lead to extend the treatment beyond the expected duration and also create doubts about the efficiency of the drug. CONCLUSIONS It seems wise to choose a drug that does not contain benzalkonium chloride when it comes to treat an allergic conjunctivitis. However, if this is not possible, the ophthalmologist must be aware of this risk when it comes to the clinical evaluation of the patient. REFERENCE : Vidal® expert database 2013 No conflict of interest .
Load more

Recommended publications
  • Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers with Topical Pharmaceutical Agents
    Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents Author Watts, Annabelle M, Cripps, Allan W, West, Nicholas P, Cox, Amanda J Published 2019 Journal Title FRONTIERS IN PHARMACOLOGY Version Version of Record (VoR) DOI https://doi.org/10.3389/fphar.2019.00294 Copyright Statement © Frontiers in Pharmacology 2019. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version. Downloaded from http://hdl.handle.net/10072/386246 Griffith Research Online https://research-repository.griffith.edu.au fphar-10-00294 March 27, 2019 Time: 17:52 # 1 REVIEW published: 29 March 2019 doi: 10.3389/fphar.2019.00294 Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents Annabelle M. Watts1*, Allan W. Cripps2, Nicholas P. West1 and Amanda J. Cox1 1 Menzies Health Institute Queensland, School of Medical Science, Griffith University, Southport, QLD, Australia, 2 Menzies Health Institute Queensland, School of Medicine, Griffith University, Southport, QLD, Australia Allergic rhinitis (AR) is a chronic upper respiratory disease estimated to affect between 10 and 40% of the worldwide population. The mechanisms underlying AR are highly complex and involve multiple immune cells, mediators, and cytokines. As such, the development of a single drug to treat allergic inflammation and/or symptoms is confounded by the complexity of the disease pathophysiology. Complete avoidance of allergens that trigger AR symptoms is not possible and without a cure, the available therapeutic options are typically focused on achieving symptomatic relief.
    [Show full text]
  • Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis
    Journal of Allergy Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Guest Editors: Ralph Mösges, Carlos E. Baena-Cagnani, and Desiderio Passali Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Journal of Allergy Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Guest Editors: Ralph Mosges,¨ Carlos E. Baena-Cagnani, and Desiderio Passali Copyright © 2014 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Journal of Allergy.” All articles are open access articles distributed under the Creative Commons At- tribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board William E. Berger, USA Alan P. Knutsen, USA Fabienne Ranc, France Kurt Blaser, Switzerland Marek L. Kowalski, Poland Anuradha Ray, USA Eugene R. Bleecker, USA Ting Fan Leung, Hong Kong Harald Renz, Germany JandeMonchy,TheNetherlands Clare M Lloyd, UK Nima Rezaei, Iran Frank Hoebers, The Netherlands Redwan Moqbel, Canada Robert P. Schleimer, USA StephenT.Holgate,UK Desiderio Passali, Italy Massimo Triggiani, Italy Sebastian L. Johnston, UK Stephen P. Peters, USA Hugo Van Bever, Singapore Young J. Juhn, USA David G. Proud, Canada Garry Walsh, United Kingdom Contents Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis,RalphMosges,¨ Carlos E. Baena-Cagnani, and Desiderio Passali Volume 2014, Article ID 416236, 2 pages Clinical Efficacy of a Spray Containing Hyaluronic Acid and Dexpanthenol after Surgery in the Nasal Cavity (Septoplasty, Simple Ethmoid Sinus Surgery, and Turbinate Surgery), Ina Gouteva, Kija Shah-Hosseini, and Peter Meiser Volume 2014, Article ID 635490, 10 pages The Effectiveness of Acupuncture Compared to Loratadine in Patients Allergic to House Dust ,Mites Bettina Hauswald, Christina Dill, Jurgen¨ Boxberger, Eberhard Kuhlisch, Thomas Zahnert, and Yury M.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Comparison of Intramuscular Betamethasone and Oral
    Color profile: Disabled Composite Default screen 100 ORIGINAL ARTICLE 100 95 95 75 75 25 25 5 5 0 Comparison of intramuscular 0 betamethasone and oral prednisone in the prevention of relapse of acute asthma John S Chan MD1, Robert L Cowie MD1, Gerald C Lazarenko MD2, Cinde Little RRT1, Sandra Scott RRT1, Gordon T Ford MD FCCP1 1Division of Respiratory Medicine and 2Department of Emergency Medicine, University of Calgary, Calgary, Alberta JS Chan, RL Cowie, GC Lazarenko, C Little, S Scott, tively) and use of inhaled corticosteroids (46% versus 64.3% GT Ford. Comparison of intramuscular betamethasone respectively) (P<0.05). Using intention-to-treat analysis, the and oral prednisone in the prevention of relapse of acute relapse rates for betamethasone and prednisone at day 7 were asthma. Can Respir J 2001;8(3):147-152. 14.9% (13 of 87 patients) and 25% (21 of 84 patients), respectively (P=0.1), and at day 21, the rates were 36.8% (32 OBJECTIVE: To compare the relapse rate after a single intra- of 87 patients) and 31% (26 of 84 patients), respectively muscular injection of a long acting corticosteroid, betametha- (P=0.4). There were no differences in symptom score, peak sone, with oral prednisone in patients discharged from the flows and adverse effects between the two groups at days 7 emergency department (ED) for acute exacerbations of and 21. asthma. CONCLUSIONS: A single dose of intramuscular betametha- PATIENTS AND METHODS: Patients with acute exacer- sone 12 mg was safe and as efficacious as prednisone in pre- bations of asthma who were suitable for discharge from the venting the relapse of acute asthma.
    [Show full text]
  • Long-Term Budesonide Or Nedocromil Mineral Accretion Over a Period of Years
    term inhaled corticosteroid (ICS) treatment on bone Long-term Budesonide or Nedocromil mineral accretion over a period of years. Treatment, Once Discontinued, Does Not Alter the Course of Mild to Moderate Asthma in STUDY POPULATION. Cohort follow-up study for a median Children and Adolescents of 7 years with 877 children 5 to 12 years of age who Strunk RC, Sternberg AL, Szefler SJ, et al. J Pediatr. had mild-to-moderate asthma and initially were ran- 2009;154(5):682–687 domly assigned in the Childhood Asthma Management Program. PURPOSE OF THE STUDY. To determine whether long-term, METHODS. Serial dual-energy x-ray absorptiometry scans continuous use of inhaled antiinflammatory medications of the lumbar spine to assess bone mineral density were affects asthma outcomes in children with mild-to-mod- performed for all patients. Annual bone mineral accre- erate asthma after use is discontinued. tion was calculated for 531 boys and 346 girls. STUDY POPULATION. A total of 941 children, 5 to 12 years of RESULTS. Oral corticosteroid bursts produced dose- age, who had previously participated in the Childhood dependent reductions in bone mineral accretion (0.052, Asthma Management Program (CAMP). 0.049, and 0.046 g/cm2 per year with 0, 1–4, and Ն5 courses, respectively) and increases in the risk for osteo- METHODS. During the CAMP trial, subjects received treat- penia (10%, 14%, and 21%, respectively) in boys but ment with budesonide, nedocromil, or placebo for 4.3 not girls. Cumulative ICS use was associated with a small years. During the posttrial period, asthma manage- decrease in bone mineral accretion in boys but not girls ment was provided by primary care physicians ac- but no increased risk for osteopenia.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Allergies Your Amerigroup Community Care Patients May Experience a Pharmacy Claim Rejection When Prescribed Nonpreferred Products
    Provider update Hot Tip: Allergies Your Amerigroup Community Care patients may experience a pharmacy claim rejection when prescribed nonpreferred products. To avoid additional steps or delays at the pharmacy, consider prescribing preferred products whenever possible. Utilization Management edits may apply to select preferred products. Coverage should be verified by reviewing the Preferred Drug List (PDL) on the Amerigroup provider website. The PDL is subject to change quarterly. Therapeutic class Preferred products Nonpreferred products Oral • Fexofenadine (generic Allegra) • Cetirizine (generic Zyrtec) antihistamines1 • Fexofenadine/ pseudoephedrine • Cetirizine/pseudoephedrine (generic Allegra-D) (generic Zyrtec D) • Loratadine (generic Claritin) • Zyrtec (cetirizine) • Loratadine/pseudoepherine • Zyrtec D (cetirizine/ (generic Claritin D) pseudoephedrine) • Clarinex (desloratadine) • Desloratadine (generic Clarinex) • Alegra (fexofenadine) • Allegra D (fexofenadine/ pseudoephedrine) • Levocetirizine (generic Xyzal) • Xyzal (levocetirizine) • Claritin (loratadine) • Claritin D (loratadine/ pseudoephedrine) Nasal steroids2 • OTC budesonide nasal spray • Flonase Sensimist (fluticasone (generic Rhinocort) furoate) • OTC Rhinocort Allergy • Flonase (fluticasone propionate) (budesonide) • Rx fluticasone propionate (generic • OTC fluticasone propionate Rx Flonase) (generic Flonase) • Mometasone furoate (generic • OTC triamcinolone acetonide Nasonex) (generic Nasacort) • Nasacort (triamcinolone acetonide) • Nasonex (mometasone furoate) • Omnaris
    [Show full text]
  • Rhinitis - Allergic (1 of 15)
    Rhinitis - Allergic (1 of 15) 1 Patient presents w/ signs & symptoms of rhinitis 2 • Consider other classifi cations of rhinitis DIAGNOSIS No - Please see Rhinitis Is allergic rhinitis - Nonallergic disease confi rmed? management chart Yes 3 ASSESS DURATION & SEVERITY OF ALLERGIC RHINITIS A Non-pharmacological therapy • Allergen avoidance • Patient education VAS <5 VAS ≥5 B Pharmacological therapy B Pharmacological therapy • Antihistamines (oral/nasal), &/or • Corticosteroids (nasal), w/ or without • Corticosteroids (nasal), or • Antihistamines (nasal), or • Cromone (nasal), or • LTRA • Leukotriene receptor antagonists (LTRA)MIMS TREATMENT © See next page Specifi cally for patients w/ asthma Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B167 © MIMS Pediatrics 2020 Rhinitis - Allergic (2 of 15) Previously treated symptomatic Previously treated symptomatic patient (VAS <5) on antihistamines patient (VAS ≥5) on intensifi ed (oral/nasal) &/or corticosteroids (nasal) therapy w/ corticosteroids (nasal) w/ or without antihistamines (nasal) Intermittent Persistent symptoms, symptoms or without allergen w/ allergen exposure exposure B Pharmacological therapy B Pharmacological therapy • Step down or discontinue therapy • Continue or step up therapy Untreated REASSESS DISEASE SEVERITY VAS symptomatic patient DAILY UP TO DAY 3 (VAS <5 or ≥5) 4 CONTINUE Yes THERAPY & STEP EVALUATION VAS <5 DOWN THERAPY1 Improvement of symptoms? No VAS ≥5 B Pharmacological therapy • Step-up therapy REASSESS DISEASE SEVERITY MIMSVAS DAILY UP TO DAY 7 4 Yes EVALUATION VAS <5 Improvement of symptoms? No TREATMENT © VAS ≥5 See next page Continue therapy if symptomatic; consider step-down or discontinuation of therapy if symptoms subside Not all products are available or approved for above use in all countries.
    [Show full text]
  • Therapeutic Class Overview Intranasal Histamine H1-Receptor Antagonists (Antihistamines)
    Therapeutic Class Overview Intranasal Histamine H1-receptor Antagonists (Antihistamines) Therapeutic Class • Overview/Summary: The four intranasal histamine-1 receptor antagonist (H1-antihistamines) products that are approved for the management of rhinitis include azelastine (Astelin®, Astepro®), olopatadine (Patanase®) and azelastine hydrochloride/fluticasone propionate (Dymista®).1-4 Allergic rhinitis, often referred to as rhinosinusitis, is a condition characterized by episodes of sneezing, rhinorrhea, nasal congestion, itchy and watery eyes, nose and palate. Other common symptoms may include cough, postnasal drip, and fatigue.5 Allergic rhinitis is also referred to in terms of the cyclical or persistent nature of symptoms. Seasonal allergic rhinitis is that which occurs at a particular time of the year; whereas, perennial allergic rhinitis describes symptoms that are present year round. Mast cell activation, histamine release, prostaglandin and leukotrienes propagation, along with other cytokine mediators (e.g., platelet activating factor, tumor necrosis factor, transforming growth factor beta, eosinophils, etc.) are known to play a direct role in the disease pathology and symptomatology.6 Allergic rhinitis may be classified by its intermittent or persistent pattern and by severity (mild or moderate to severe). Intermittent patterns involve the presence of symptoms for less than four days per week or for less than four weeks; whereas persistent patterns entail the presence of symptoms more than four days per week and for more than four weeks. Conditions associated with allergic rhinitis include: allergic conjunctivitis, sinusitis, asthma, atopic dermatitis, oral allergy syndrome, eustachian tube dysfunction, sleep disturbances, nasal obstruction leading to anosmia, and migraine headaches.5,7 Astelin® nasal spray is the only agent within the class that is available generically.
    [Show full text]
  • FDA Briefing Document Pulmonary-Allergy Drugs Advisory Committee Meeting
    FDA Briefing Document Pulmonary-Allergy Drugs Advisory Committee Meeting August 31, 2020 sNDA 209482: fluticasone furoate/umeclidinium/vilanterol fixed dose combination to reduce all-cause mortality in patients with chronic obstructive pulmonary disease NDA209482/S-0008 PADAC Clinical and Statistical Briefing Document Fluticasone furoate/umeclidinium/vilanterol fixed dose combination for all-cause mortality DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought the supplemental New Drug Application (sNDA) 209482, for fluticasone furoate/umeclidinium/vilanterol, as an inhaled fixed dose combination, for the reduction in all-cause mortality in patients with COPD, to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered
    [Show full text]
  • Protective Effects of Inhaled Ipratropium Bromide on Bronchoconstriction Induced by Adenosine and Methacholine in Asthma
    Eur Aesplr J 1992, 5, 56()-665 Protective effects of inhaled ipratropium bromide on bronchoconstriction induced by adenosine and methacholine In asthma N. Crimi, F. Palermo, R. Oliveri, R. Polosa, I. Settinieri, A. Mistretta Protective effects of inhaled ipratropium bromide on bronchoconstriction induced by Istituto di Malattie dell' Apparato adenosine and methacholine in asthma. N. Crimi, F. Palermo, R. Oliveri, R. Po/osa, Respiratorio e Tisiologia, Universita' di Catania, Catania, Italy. I. Seuinier~ A. Mistretta. ABSTRACT: Although adenosine-Induced bronchoconstrictlon is mainly due to Correspondence: N. Crimi mast cell mediator release, vagal reflexes have also been Implicated in this Istituto di Malattie dell' Appara.to response. Respiratorio e Tisiologia We have Investigated the effect of a speciflc muscarlnlc-receptor antagonist, Universita' di Catania ipratroplum bromide, on methacholine- and adenosine-Induced bronchoconstriction Via Passo Gravina 187 In a randomized, placebo-controlled, double-blind study of 12 asthmatic subjects. 95125 Catania Airway response was evaluated as forced expiratory volume in one second (FEV,). Italy Inhaled lpratroplum bromide (40 Jlg), administered 20 mln prior to bronchoprovocation, Increased the provocation dose of Inhaled methacholine and Keywords: Adenosine adenosine required to reduce FEV, by 20% from baseline (PD,.) from 0.11 to 0.79 asthma ipratropium bromide mg (p<O.Ol) and from 0.57 to 1.27 mg (p<0.01), respectively. The mean baseline methacholine FEV, values after administration of lpratroplum bromide were signlfkantly higher than after placebo administration (p<O.OS). However, there was no correlation Received: May 22 1991 between the degree of bronchodllatatlon and dose-ratios for methacholine and Accepted after revision January 7 1992 adenosine.
    [Show full text]
  • Core Safety Profile
    Core Safety Profile Active substance: Nedocromil Pharmaceutical form(s)/strength: Eye drops: 20 mg/ml, Inhalation vapour: 5 mg/ml, Pressurised inhalation: 2 mg/dose, 2mg/0,1 mg, Nebuliser solution: 10 mg/2 ml, Inhalation powder: 10 mg/dose, Nasal spray: 10 mg/ml P-RMS: CZ/H/PSUR/0016/001 Date of FAR: 09.10.2010 EU Core Safety Profile (CSP) For Nedocromil sodium NB: This CSP is combining safety information from the three existing pharmaceutical forms: Eye drops, Nasal spray and Inhaler. Information that is specific to one form is identified by a subheading. No subheading indicates that information is valid for all pharmaceuticals forms 4.3 Contraindications For eye drops <Product name> eye drops is contraindicated in patients with known hypersensitivity to nedocromil sodium, benzalkonium chloride or other constituents of the formulation. For Nasal spray and Inhaler <Product name> nasal spray or inhaler is contraindicated in patients with known hypersensitivity to any of the constituents. 4.4 Special warnings and precautions for use For eye drops Patients should be advised not to wear soft contact lenses during treatment with <product name> eye drops. Benzalkonium chloride, a constituent of the formulation, may accumulate in soft contact lenses. This preservative, when slowly released, could possibly irritate the cornea. In patients who continue to wear hard or gas permeable contact lenses during <product name> eye drops treatment, the lenses should be taken out of the eye prior to instillation of the drops. They should be inserted again not earlier than 10 minutes after administration, in order to allow an even conjunctival distribution of the solution.
    [Show full text]